文献速递药物相互作用

伊曲康唑对宗格替尼药代动力学的影响

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.
PubMed 文献 · Pharmacotherapy · 2026-01-01

本研究在健康男性志愿者中开展开放标签、两周期、固定序列的药物相互作用试验,评估多剂量伊曲康唑对单次口服15 mg宗格替尼药代动力学的影响。结果显示,联用伊曲康唑后宗格替尼AUC0-∞和Cmax的几何均值比分别为141.2%和126.9%,总暴露量轻度增加,但鉴于其宽治疗窗,被认为无临床相关性,批准剂量120 mg无需调整。

要点

  • 伊曲康唑使宗格替尼AUC0-∞增加至141.2%,Cmax增加至126.9%。
  • 暴露量轻度增加,因治疗窗宽,判为无临床相关性。
  • 与CYP3A/P-gp抑制剂联用时,宗格替尼120 mg无需调整剂量。

核心结论

  • 联用伊曲康唑导致宗格替尼总暴露量轻度增加,但无临床相关性。
  • 批准剂量120 mg宗格替尼与CYP3A/P-gp抑制剂联用无需剂量调整。

研究设计与样本

  • 开放标签、两周期、固定序列的临床药物相互作用研究。
  • 16名健康男性参与者先后接受单次15 mg宗格替尼(参照)及联用多剂量伊曲康唑(试验)。

主要发现

  • 宗格替尼AUC0-∞的试验/参照几何均值比为141.2%(90% CI: 126.3-157.7%)。
  • AUC0-tz的几何均值比为142.8%(90% CI: 126.0-161.9%)。
  • Cmax的几何均值比为126.9%(90% CI: 106.6-151.0%)。

关键数值与推荐

  • 主要终点为AUC0-∞和Cmax,次要终点为AUC0-tz。
  • 药物相互作用程度用调整几何均值比(90% CI)评估。

临床怎么用

  • 临床使用宗格替尼120 mg时,无需因联用强CYP3A或P-gp抑制剂而调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Zongertinib is an irreversible tyrosine kinase inhibitor that selectively inhibits human epidermal growth factor receptor 2 (HER2) while sparing wild-type epidermal growth factor receptor (EGFR), thereby minimizing associated toxicities. Oxidative hepatic metabolism of zongertinib in vitro is principally driven by cytochrome P450 (CYP) 3A. It is necessary, therefore, to assess the effect of a strong CYP3A inhibitor on the pharmacokinetics of zongertinib in humans. OBJECTIVE: This study investigated the effect of multiple oral doses of the strong CYP3A inhibitor and regulatory-recommended probe inhibitor of P-glycoprotein (P-gp), itraconazole, on the pharmacokinetics of a single dose of zongertinib in healthy male participants. METHODS: This open-label, two-period, fixed-sequence, clinical drug-drug interaction study assessed the pharmacokinetics of a 15 mg oral dose of zongertinib in the absence and presence of multiple oral doses of itraconazole. The extent of drug-drug interaction was estimated using the adjusted geometric mean (gMean) ratios (90% confidence intervals [CIs]) for the test (T) treatment (zongertinib and itraconazole) vs. the reference (R) treatment (zongertinib alone). Primary endpoints were the area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) and the maximum measured plasma concentration (Cmax) of zongertinib. The secondary pharmacokinetic endpoint was AUC for zongertinib from time 0 to the last quantifiable time point (AUC0-tz). RESULTS: Sixteen participants received zongertinib alone (Period 1, R), followed by co-administration with itraconazole (Period 2, T). In terms of zongertinib exposure, the gMean ratio of T to R was 141.2% (90% CI: 126.3-157.7%) for AUC0-∞, 142.8% (90% CI: 126.0-161.9%) for AUC0-tz, and 126.9% (90% CI: 106.6-151.0%) for Cmax. CONCLUSION: Co-administration with itraconazole resulted in a mild increase in total exposure to zongertinib that was not considered clinically relevant given its wide therapeutic window. These data indicate that the approved 120 mg dose of zongertinib can be administered without dose adjustment in combination with CYP3A/P-gp inhibitors.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Scudamore O, Wind S, Grempler R, et al. The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers. Pharmacotherapy. 2026. PMID: 42324472. doi:10.1002/phar.70182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。